2024
Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities
Kewan T, Stahl M, Bewersdorf J, Zeidan A. Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities. Current Hematologic Malignancy Reports 2024, 19: 138-150. PMID: 38632155, DOI: 10.1007/s11899-024-00733-y.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationAllogeneic hematopoietic stem cell transplantationLower-risk MDSErythropoiesis-stimulating agentsHypomethylating agentsIPSS-MHR-MDSRisk stratificationMolecular International Prognostic Scoring SystemRisk of leukemia progressionTreated with hypomethylating agentsInternational Prognostic Scoring SystemTreatment of myelodysplastic syndromesOral hypomethylating agentsHigh-risk MDSPrognostic Scoring SystemStem cell transplantationEnhanced risk stratificationRecent FindingsRecent advancesRefine treatment strategiesQuality-of-life improvementAssociated with treatmentTreatment decision-makingIntensive chemotherapyMDS patients
2023
Comparison of the Revised 4 Th (2016) and 5 Th (2022) Editions of the World Health Organization (WHO) Classification in a Cohort of Patients with Lower-Risk Myelodysplastic Syndromes/Neoplasms (MDS) - a Glam Registry (REGLAM) Analysis
Iastrebner M, Zeidan A, Arbelbide J, Velloso E, Pereira T, Boada M, Crisp R, Pereyra P, Reyes J, Zappa M, perez-Jacobo F, Dela Peña Celaya J, Moreno E, Abello V, Solano M, Cuervo D, Espinosa D, Casas C, Montoya L, Enrico A, Prates V, Chavez E, Ontiveros-Austria J, Kornblihtt L, Leon A, Toledo V, Negri L, Serrano J, Sánchez A, Rodriguez-Zuñiga A, Stevenazzi M, Goldschmidt V, Grille S. Comparison of the Revised 4 Th (2016) and 5 Th (2022) Editions of the World Health Organization (WHO) Classification in a Cohort of Patients with Lower-Risk Myelodysplastic Syndromes/Neoplasms (MDS) - a Glam Registry (REGLAM) Analysis. Blood 2023, 142: 5179. DOI: 10.1182/blood-2023-185122.Peer-Reviewed Original ResearchProgression-free survivalTime of diagnosisAcute myeloid leukemiaMDS-MLDOverall survivalMDS patientsMDS-RSInternational Prognostic Scoring SystemLow-risk MDS patientsWorld Health Organization classificationLR-MDS patientsMedian blast countRisk MDS patientsCohort of patientsKaplan-Meier methodPrognostic scoring systemClassification of patientsNon-Hispanic whitesMDS-EB2PFS probabilityWHO 2016Baseline characteristicsBlast countMedian ageMeier methodCombining Gene Mutation with Transcriptomic Data Improves Outcome Prediction in Myelodysplastic Syndromes
Sauta E, Zampini M, Dall'Olio D, Sala C, Todisco G, Travaglino E, Lanino L, Tentori C, Maggioni G, D'Amico S, Asti G, Dall'Olio L, Mosca E, Ubezio M, Campagna A, Riva E, Bicchieri M, Savevski V, Santoro A, Kordasti S, Santini V, Diez-Campelo M, Kubasch A, Platzbecker U, Fenaux P, Zhao L, Zeidan A, Haferlach T, Castellani G, Della Porta M. Combining Gene Mutation with Transcriptomic Data Improves Outcome Prediction in Myelodysplastic Syndromes. Blood 2023, 142: 1863. DOI: 10.1182/blood-2023-186222.Peer-Reviewed Original ResearchAcute myeloid leukemiaProportional hazards modelOverall survivalClinical outcomesMyelodysplastic syndromeClinical featuresMDS patientsPrognostic informationConcordance indexCox proportional hazards modelConventional prognostic scoresIPSS-R scorePrimary end pointBone marrow blastsHarrell's concordance indexPeripheral blood cytopeniasPrognostic scoring systemRisk of progressionAdditional prognostic informationCytogenetic alterationsGene mutationsIndividual patient levelSame clinical phenotypeBlood cytopeniasMarrow blastsNovel Approaches and Future Directions in Myelodysplastic Syndrome Treatment
Bewersdorf J, Xie Z, Zeidan A. Novel Approaches and Future Directions in Myelodysplastic Syndrome Treatment. The Cancer Journal 2023, 29: 195-202. PMID: 37195776, DOI: 10.1097/ppo.0000000000000658.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHigh-risk MDS patientsInternational Prognostic Scoring SystemPhase III clinical trialsErythropoiesis-stimulating agentsPrognostic scoring systemRisk stratification toolAdvanced clinical testingStandard of careAcute myeloid leukemiaTelomerase inhibitor imetelstatEncouraging early resultsMyelodysplastic Syndromes TreatmentAnemic patientsAgent monotherapyMDS patientsStratification toolSyndrome treatmentCombination therapyDysplastic changesClinical trialsMyeloid leukemiaTreatment decisionsClonal disorderTreatment selectionClinical testingCurrent landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)
Bewersdorf J, Xie Z, Bejar R, Borate U, Boultwood J, Brunner A, Buckstein R, Carraway H, Churpek J, Daver N, Porta M, DeZern A, Fenaux P, Figueroa M, Gore S, Griffiths E, Halene S, Hasserjian R, Hourigan C, Kim T, Komrokji R, Kuchroo V, List A, Loghavi S, Majeti R, Odenike O, Patnaik M, Platzbecker U, Roboz G, Sallman D, Santini V, Sanz G, Sekeres M, Stahl M, Starczynowski D, Steensma D, Taylor J, Abdel-Wahab O, Xu M, Savona M, Wei A, Zeidan A. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). Blood Reviews 2023, 60: 101072. PMID: 36934059, DOI: 10.1016/j.blre.2023.101072.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsImmune checkpoint inhibitorsSpecific molecular alterationsNovel animal modelInnate immune systemCheckpoint inhibitorsImmune dysregulationMDS patientsClinical trialsNovel therapiesTherapeutic strategiesAnimal modelsGermline predispositionImmune systemMolecular alterationsClinical researchInternational ConsortiumNeoplasmsClinical workGenetic landscapeInternational WorkshopPatientsCurrent landscapePathogenesisTherapyDisease
2022
Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS)
Brunner A, Gavralidis A, Ali N, Hunter A, Komrokji R, Zeidan A, Sallman D. Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS). Blood Cancer Journal 2022, 12: 153. PMID: 36379923, PMCID: PMC9666661, DOI: 10.1038/s41408-022-00748-9.Peer-Reviewed Original ResearchConceptsPartial hematologic recoveryMyelodysplastic syndromeHematologic recoveryResponse criteriaCR/CRhIWG 2006 criteriaDuration of therapyBest overall responseTime of therapyCR responseCRH responseDNMTi therapyOS associationComplete remissionMedian OSOverall survivalAdult patientsAllogeneic transplantsMedian ageMDS patientsMultivariable analysisClinical trialsSimilar survivalPatientsTherapyMDS-529 The Prognostic Value of the Endothelial Activation and Stress Index (EASIX) Score, Platelet-to-Lymphocyte Ratio (PLR), and Neutrophil-to-Lymphocyte (NLR) in Myelodysplastic Syndrome Patients in Jordan after Adjusting for IPSS-R Risk Groups
Alrawabdeh J, Alzu'bi M, Hamadneh Y, Odeh N, Alzyoud M, Awidi A, Magableh A, Alshorman A, Al-Fararjeh F, Aladily T, Zeidan A, Bawa'neh H. MDS-529 The Prognostic Value of the Endothelial Activation and Stress Index (EASIX) Score, Platelet-to-Lymphocyte Ratio (PLR), and Neutrophil-to-Lymphocyte (NLR) in Myelodysplastic Syndrome Patients in Jordan after Adjusting for IPSS-R Risk Groups. Clinical Lymphoma Myeloma & Leukemia 2022, 22: s321. DOI: 10.1016/s2152-2650(22)01428-8.Peer-Reviewed Original ResearchPlatelet-lymphocyte ratioNeutrophil-lymphocyte ratioEASIX scoreMyelodysplastic syndromeFisher's exact testMDS patientsExact testStress Index scoresMedian ageEndothelial activationPrognostic valueFemale ratioRisk groupsIndex scoreMDS/MPN patientsAvailable prognostic systemsMultivariable Cox regressionJordan University HospitalMyelodysplastic syndrome patientsReferral centerIndependent predictorsAML transformationLymphocyte ratioCox regressionUnfavorable prognosisPatient Preferences for Benefits, Risks, and Administration Route of Hypomethylating Agents in Myelodysplastic Syndromes
Zeidan AM, Tsai JH, Karimi M, Schmier J, Jayade S, Zormpas E, Hassan A, Ruiters D, Anthony C, Hill K, Wert T, Botteman M. Patient Preferences for Benefits, Risks, and Administration Route of Hypomethylating Agents in Myelodysplastic Syndromes. Clinical Lymphoma Myeloma & Leukemia 2022, 22: e853-e866. PMID: 35729009, DOI: 10.1016/j.clml.2022.04.023.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromePatient preferencesRelative attribute importanceRisk of AMLPatient advocacy group representativesAdministration burdenLevel of fatigueMode of administrationDCE choice tasksAML transformationMDS patientsSurvey patientsOral pillsCanadian patientsAdvocacy group representativesHypomethylating agentNumber of visitsAdministration frequencyAdministration routePatient proxyPatientsEquivalent effectivenessMDS riskAdministration methodsSame risk
2021
Injectable Hypomethylating Agents for Management of Myelodysplastic Syndromes: Patients’ Perspectives on Treatment
Zeidan AM, Jayade S, Schmier J, Botteman M, Hassan A, Ruiters D, Hill K, Joshi N. Injectable Hypomethylating Agents for Management of Myelodysplastic Syndromes: Patients’ Perspectives on Treatment. Clinical Lymphoma Myeloma & Leukemia 2021, 22: e185-e198. PMID: 34674983, DOI: 10.1016/j.clml.2021.09.009.Peer-Reviewed Original ResearchConceptsMDS patientsAdult MDS patientsMedian patient agePain/discomfortMost MDS patientsOnline cross-sectional surveyDaily activitiesCross-sectional surveyPatient advocacy groupsPatient ageMyelodysplastic syndromeSC administrationSubcutaneous administrationTreatment administrationSC therapyTreatment challengesPatient's perspectiveHypomethylating agentRisk scoreHMA treatmentMD treatmentPatientsAdministrationAzacitidinePain
2020
Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey
Pine AB, Chokr N, Stahl M, Steensma DP, Sekeres MA, Litzow MR, Luger SM, Stone RM, Greenberg PL, Bejar R, Bewersdorf JP, Gore SD, Zeidan AM. Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey. Leukemia & Lymphoma 2020, 61: 1455-1464. PMID: 32026740, DOI: 10.1080/10428194.2020.1723013.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeRisk stratificationMolecular profilingNext-generation sequencingWeb-based surveyRole of NGSManagement of patientsUtility of NGSEvidence-based guidelinesHealth care providersLarge web-based surveyMDS patientsPractice patternsTreatment decisionsCare providersResponse assessmentProviders' beliefsPatientsInstitutional guidelinesGene mutationsDiagnosisSyndromeTesting logisticsInterpretation of resultsWide variation
2019
Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents
Zeidan AM, Hu X, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Bewersdorf JP, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents. Leukemia & Lymphoma 2019, 61: 397-408. PMID: 31570040, PMCID: PMC7732188, DOI: 10.1080/10428194.2019.1663423.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeOverall survivalHMA cyclesHMA therapyProvider experienceCox proportional hazards modelOlder MDS patientsMedian overall survivalPercent of patientsSEER-Medicare dataMultivariate logistic regressionProportional hazards modelHMA initiationClinical outcomesMDS patientsClinical trialsMedian numberHMA treatmentHazards modelPatientsSignificant associationLogistic regressionPopulation-level survivalSurvivalSyndromeRBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis
Zeidan AM, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis. Leukemia & Lymphoma 2019, 60: 3181-3187. PMID: 31170846, DOI: 10.1080/10428194.2019.1622700.Peer-Reviewed Original ResearchConceptsRBC transfusion independenceLR-MDS patientsTransfusion independenceHMA initiationRBC transfusionClinical effectivenessReal-life clinical effectivenessRed blood cell transfusionLower-risk myelodysplastic syndromesLow-risk MDS patientsRisk MDS patientsBlood cell transfusionRisk myelodysplastic syndromesHMA therapyLR-MDSCell transfusionMost patientsDisease courseMDS patientsMedicare databaseMyelodysplastic syndromePopulation-level estimatesLower oddsTransfusionPatients
2018
Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a Large Web-Based Survey
Pine A, Chokr N, Stahl M, Steensma D, Sekeres M, Litzow M, Luger S, Stone R, Greenberg P, Bejar R, Gore S, Zeidan A. Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a Large Web-Based Survey. Blood 2018, 132: 1825. DOI: 10.1182/blood-2018-99-113888.Peer-Reviewed Original ResearchGene mutation profilingSouthwest Oncology GroupMyelodysplastic syndromeRisk stratificationHealth care providersMutation profilingOncology GroupMDS patientsClinical trialsCare providersWeb-based surveyConsensus evidence-based guidelinesInternational Prognostic Scoring SystemEastern Cooperative Oncology GroupGene panelAdvisory CommitteeConventional prognostic modelsThird of respondersHigh-risk patientsCooperative Oncology GroupPrognostic scoring systemRisk stratification toolManagement of patientsStem cell transplantEvidence-based guidelinesTo chelate or not to chelate in MDS: That is the question!
Zeidan AM, Griffiths EA. To chelate or not to chelate in MDS: That is the question! Blood Reviews 2018, 32: 368-377. PMID: 29602612, DOI: 10.1016/j.blre.2018.03.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsIron chelation therapyMyelodysplastic syndromeIron overloadMDS patientsChronic transfusion supportAcute myeloid leukemiaBone marrow failureDisease-related alterationsTransfusion supportSurvival impactRandomized trialsInferior outcomesMyeloid leukemiaChelation therapyClinical consequencesMarrow failurePatientsHeterogeneous groupIron metabolismTherapyInherent risksSyndromePhysical manifestationsLeukemiaHemopathies
2017
Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome
Zeidan AM, Pullarkat VA, Komrokji RS. Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome. Critical Reviews In Oncology/Hematology 2017, 117: 57-66. PMID: 28807236, DOI: 10.1016/j.critrevonc.2017.07.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsIron chelation therapyIron overloadMyelodysplastic syndromeFrequent red blood cell transfusionsLower-risk myelodysplastic syndromesRed blood cell transfusionLow-risk MDS patientsHeterogeneous hematopoietic neoplasmsRandomized trial evidenceBlood cell transfusionAcute myeloid leukemiaTissue iron depositionCell transfusionSupportive careMDS patientsTrial evidenceMyeloid leukemiaChelation therapyThalassemia patientsIneffective erythropoiesisBetter survivalPatientsEndocrine toxicityIron depositionHematopoietic neoplasmsComparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium
Zeidan AM, Al Ali N, Barnard J, Padron E, Lancet JE, Sekeres MA, Steensma DP, DeZern A, Roboz G, Jabbour E, Garcia-Manero G, List A, Komrokji R. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium. Leukemia 2017, 31: 1391-1397. PMID: 28111463, DOI: 10.1038/leu.2017.33.Peer-Reviewed Original ResearchConceptsInternational Prognostic Scoring SystemT-MDS patientsDe novo myelodysplastic syndromePrognostic scoring systemNovo myelodysplastic syndromeMyelodysplastic syndromeT-MDSClinical outcomesScoring systemMDS Clinical Research ConsortiumClinical Research ConsortiumRisk stratification toolRisk group categoriesRisk stratification modelConventional risk stratification modelPrognostic systemPrior therapyMedian survivalIndolent courseInferior survivalMDS patientsPrognostic utilityStratification toolWorse outcomesPatients
2016
Intensity of end‐of‐life care for patients with myelodysplastic syndromes: Findings from a large national database
Fletcher SA, Cronin AM, Zeidan AM, Odejide OO, Gore SD, Davidoff AJ, Steensma DP, Abel GA. Intensity of end‐of‐life care for patients with myelodysplastic syndromes: Findings from a large national database. Cancer 2016, 122: 1209-1215. PMID: 26914833, DOI: 10.1002/cncr.29913.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overCause of DeathCritical IllnessDatabases, FactualFemaleHospice CareHumansIntensive Care UnitsLogistic ModelsMaleMultivariate AnalysisMyelodysplastic SyndromesOdds RatioPatient Care TeamQuality of Health CareRetrospective StudiesRisk AssessmentSEER ProgramSex FactorsSurvival AnalysisTerminal CareUnited StatesConceptsMyelodysplastic syndromeDays of lifeHospice enrollmentLife careEnd Results-Medicare databaseIntensive care unit admissionEOL quality measuresIntensity of endIntensity of EOLCare unit admissionTransfusion-dependent patientsLarge national databaseUnit admissionPalliative needsNonwhite patientsRed blood cellsMDS patientsPlatelet transfusionsHospice useEOL careHospice modelMultivariable modelLower oddsPatientsPopulation ages
2015
Quality of End-of-Life Care for the Myelodysplastic Syndromes: Findings from a Large National Database
Fletcher S, Cronin A, Zeidan A, Odejide O, Gore S, Davidoff A, Steensma D, Abel G. Quality of End-of-Life Care for the Myelodysplastic Syndromes: Findings from a Large National Database. Blood 2015, 126: 3287. DOI: 10.1182/blood.v126.23.3287.3287.Peer-Reviewed Original ResearchDays of lifeMyelodysplastic syndromeICU admissionLife careSolid tumorsTransfusion-dependent MDS patientsIntensive care unit useBlood cancersMultivariable logistic regression modelBlood pressure supportQuality of EOLMarital statusTransfusion-dependent patientsSpecific hematologic malignanciesQuality of endLarge national databaseYears of ageOdds of enrollmentLogistic regression modelsBone marrow failurePalliative needsHospice enrollmentSurveillance EpidemiologyTransfusion dependenceMDS patientsLack of Association Between Costs of Care and Overall Survival (OS) Among Medicare Beneficiaries with Myelodysplastic Syndromes (MDS) in the United States (US)
Zeidan A, Wang R, Davidoff A, Gore S, Soulos P, Huntington S, Gross C, Ma X. Lack of Association Between Costs of Care and Overall Survival (OS) Among Medicare Beneficiaries with Myelodysplastic Syndromes (MDS) in the United States (US). Blood 2015, 126: 873. DOI: 10.1182/blood.v126.23.873.873.Peer-Reviewed Original ResearchDisability Status ScoreOverall survivalMyelodysplastic syndromeMDS patientsCost of careStudy cohortLack of associationHistologic subtypeStatus scoreMedicare beneficiariesEnd Results-Medicare databaseProportional hazards regression modelsOverall study cohortMedian overall survivalOutcomes of patientsElixhauser comorbidity scoreDate of diagnosisEntire study cohortKaplan-Meier methodHazards regression modelsDisease-related costsNon-white raceEnd of studyDate of deathMedicare Part ADeferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes
Zeidan AM, Hendrick F, Friedmann E, Baer MR, Gore SD, Sasane M, Paley C, Davidoff AJ. Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes. Journal Of Comparative Effectiveness Research 2015, 4: 327-340. PMID: 26274794, PMCID: PMC5549705, DOI: 10.2217/cer.15.20.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeMortality riskDeferasirox therapyOlder MDS patientsICD-9 codesIron chelation therapyEnd of studyMarginal structural modelsTransfusion thresholdMDS patientsMedicare patientsChelation therapyMedicare claimsMedicare populationPatientsBlood unitsAbstractTextTherapySignificant reductionSyndromeRiskWeeksMortality